All In Biotech

Drug Trial Radar · NCT06588660

ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma

Phase 1b Study of ST-067 (Decoy-Resistant IL-18) With Teclistamab in Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Jul 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

1

Actual

Start

Dec 18, 2024

Primary completion

Feb 14, 2025

Study completion Feb 14, 2025

Sponsor

Lead sponsor
University of WashingtonAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Simcha Therapeutics
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase Ib trial tests the safety, side effects and best dose of ST-067 in combination with teclistamab and how well it works in treating patients with multiple myeloma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). ST-067 is an engineered variant of the human cytokine interleukin-18 that may help the immune system kill cancer cells. Teclistamab is a bispecific antibody that can bind to two different antigens at the same time. Teclistamab binds to B-cell maturation antigen (BCMA), a protein found on some B-cells and myeloma cells, and CD3 on T-cells (a type of white blood cell) and may interfere with the ability of cancer cells to grow and spread. Giving ST-067 in combination with teclistamab may be safe, tolerable and/or effective in treating patients with relapsed or refractory multiple myeloma.

Conditions

  • Recurrent Multiple Myeloma
  • Refractory Multiple Myeloma

Interventions

  • VevoctadekinBiological

    Given SC

  • Bone Marrow AspirationProcedure

    Undergo bone marrow aspiration and biopsy

  • Bone Marrow BiopsyProcedure

    Undergo bone marrow aspiration and biopsy

  • Medical Chart ReviewOther

    Ancillary studies

  • TeclistamabDrug

    Given SC

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Monotherapy dose-limiting toxicities (DLT) ratesTime frame: Up to 28 days (cycle 1)
  2. Combination therapy DLT ratesTime frame: Up to 28 days (cycle 2)
  3. Optimal biological dose (OBD)Time frame: Up to 28 days
  4. Incidence of adverse events (AEs)Time frame: Up to 30 days after last dose of ST-067

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fred Hutch/University of Washington Cancer Consortium

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.